Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
MD Wang, XJ Xu, KC Wang, YK Diao, JH Xu… - Cancer …, 2024 - Wiley Online Library
Hepatocellular carcinoma (HCC), the most prevalent malignancy of the digestive tract, is
characterized by a high mortality rate and poor prognosis, primarily due to its initial …
characterized by a high mortality rate and poor prognosis, primarily due to its initial …
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
X Liu, Y Lu, W Zhou, T Peng, J Zhou, H Bi, F Xia… - Liver Cancer, 2024 - karger.com
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
[HTML][HTML] A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma …
A Ichida, J Arita, E Hatano, S Eguchi, A Saiura… - Liver Cancer, 2024 - karger.com
Abstract Introduction: The phase III REFLECT trial demonstrated that lenvatinib was superior
to sorafenib in terms of progression-free survival (PFS), time to progression, and objective …
to sorafenib in terms of progression-free survival (PFS), time to progression, and objective …
A multidisciplinary treatment strategy with conversion surgery for hepatocellular carcinoma
H Shiozaki, K Furukawa, K Haruki… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Sorafenib was previously the only targeted therapy for hepatocellular
carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable …
carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable …
Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma
M Okuno, E Hatano, M Tada, T Nishimura… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The survival and prognostic factors in patients with advanced
hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib …
hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib …
Pembrolizumab in combination with lenvatinib in participants with hepatocellular carcinoma (HCC) before liver transplant as neoadjuvant therapY—PLENTY pilot …
Z Lv, X Xiang, J Yong, Y Zhou, Y Wu, L Li… - … Journal of Surgery, 2024 - journals.lww.com
Background: The high recurrent rate after liver transplantation (LT) remains a clinical
challenge, especially for those exceeding the Milan criteria (MC) and with high RETREAT …
challenge, especially for those exceeding the Milan criteria (MC) and with high RETREAT …
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis
H Xu, H Zhang, B Li, K Chen, Y Wei - BMC cancer, 2024 - Springer
Background Systemic conversion therapy provides patients with initially unresectable
hepatocellular carcinoma (HCC) the chance to salvage radical liver resection and superior …
hepatocellular carcinoma (HCC) the chance to salvage radical liver resection and superior …
Strategies and practice of conversion therapy for hepatocellular carcinoma
MA Chi, TAN Guang - 临床肝胆病杂志, 2024 - lcgdbzz.org
Due to the insidious onset and poor prognosis of primary liver cancer, most patients are
found to have unresectable primary liver cancer at initial diagnosis. In recent years, with the …
found to have unresectable primary liver cancer at initial diagnosis. In recent years, with the …
肝细胞癌转化治疗的策略及实践.
马驰， 谭广 - Journal of Clinical Hepatology/Linchuang …, 2024 - search.ebscohost.com
原发性肝癌因发病隐匿及预后较差, 多数初始诊断即为不可切除. 近些年, 随着靶向治疗,
免疫治疗及局部治疗等转化治疗方案的兴起, 部分中晚期肝癌患者成功转化并行根治性手术切除 …
免疫治疗及局部治疗等转化治疗方案的兴起, 部分中晚期肝癌患者成功转化并行根治性手术切除 …
Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
S Komatsu, Y Yano, T Mimura, A Minami… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Sorafenib and lenvatinib have long been used as a first-line treatment for
advanced hepatocellular carcinoma (HCC). Along with the development of systemic …
advanced hepatocellular carcinoma (HCC). Along with the development of systemic …